{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:44:22Z","timestamp":1791585862456,"version":"4.3.4"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatric-onset multiple sclerosis (POMS).<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon \u03b2-1a (IFN\u03b2-1a) in POMS.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The CONNECT study was an active-controlled, open-label, rater-blinded 96-week randomized clinical trial in patients with POMS aged 10 to less than 18 years treated between August 2014 and November 2020. Data were analyzed from January through October 2021.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized to DMF or IFN\u03b2-1a.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the proportion of patients free of new or newly enlarging (N or NE) T2 hyperintense lesions at week 96 among trial completers. Secondary end points included number of N or NE T2 lesions, proportion of patients free of relapse, annualized relapse rate (ARR), and safety. The estimated proportion of participants who were relapse free up to week 96 was calculated based on the Kaplan-Meier method. Adjusted ARR was obtained from a negative binomial regression adjusted for baseline relapse rate, baseline Expanded Disability Status Scale (EDSS) score, and age group.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 150 patients with POMS in the intention-to-treat (ITT) population (median [range] age, 15 [10-17] years; 101 [67.3%] female patients), 78 individuals received DMF and 72 individuals received IFN\u03b2-1a. At week 96, the proportion of patients with no N or NE T2 hyperintense lesions among 103 trial completers was 16.1% (95% CI, 8.0%-27.7%) for DMF vs 4.9% (95% CI, 0.6%-16.5%) for IFN\u03b2-1a, and in a sensitivity analysis among the ITT population, the proportions were 10 patients receiving DMF (12.8%) vs 2 patients receiving IFN\u03b2-1a (2.8%). The estimated proportion of patients who remained relapse free at week 96 was 66.2% for DMF vs 52.3% for IFN\u03b2-1a. Adjusted ARR (95% CI) at week 96 was 0.24 (95% CI, 0.15-0.39) for DMF vs 0.53 (95% CI, 0.33-0.84) for IFN\u03b2-1a; the rate ratio for DMF vs IFN\u03b2-1a was 0.46 (95% CI, 0.26-0.80; P<\/jats:italic>\u2009=\u2009.006). The number of treatment-emergent adverse events (TEAEs; 74 patients [94.9%] vs 69 patients [95.8%]), serious TEAEs (18 patients [23.1%] vs 21 patients [29.2%]), and treatment discontinuations due to TEAEs (5 patients [6.4%] vs 8 patients [11.1%]) was similar for DMF vs IFN\u03b2-1a.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study found that more pediatric patients with POMS treated with DMF were free of new or newly enlarging T2 lesions and that the adjusted ARR was lower among these patients compared with those treated with interferon \u03b2-1a. DMF was well tolerated.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02283853<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.30439","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:34:25Z","timestamp":1664379265000},"page":"e2230439","source":"Crossref","is-referenced-by-count":57,"title":["Effect of Dimethyl Fumarate vs Interferon \u03b2-1a in Patients With Pediatric-Onset Multiple Sclerosis"],"prefix":"10.1001","volume":"5","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[{"name":"University Lille, Inserm, Centre Hospitalier Universitaire de Lille, F\u00e9d\u00e9ratif Hospitalo-Universitaire Precise, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Scaramozza","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute, Dasman, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, Pediatric Neurology Department, University Hospitals Paris Saclay, Bic\u00eatre Hospital, Le Kremlin Bic\u00eatre, France"},{"name":"French Reference Network of Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[{"name":"Sant\u2019 Andrea Multiple Sclerosis Center, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lyons","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Mokliatchouk","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Pultz","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now with CR Medicon, Orange, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatou","family":"N\u2019Dure","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Liu","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runda","family":"Badwan","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Branco","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Hood-Humphrey","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Hanna","sequence":"additional","affiliation":[{"name":"Biogen, Maidenhead, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir-Hadi","family":"Maghzi","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"12","key":"zoi220863r1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/0883073819845827","article-title":"Epidemiology of pediatric-onset multiple sclerosis: a systematic review of the literature.","volume":"34","author":"Jeong","year":"2019","journal-title":"J Child Neurol"},{"issue":"1","key":"zoi220863r2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","article-title":"Pediatric multiple sclerosis: a review.","volume":"18","author":"Alroughani","year":"2018","journal-title":"BMC Neurol"},{"issue":"2","key":"zoi220863r3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years.","volume":"3","author":"Benson","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"zoi220863r4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol"},{"key":"zoi220863r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101511","article-title":"Factors associated with health care utilization in pediatric multiple sclerosis.","volume":"38","author":"Marrie","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"20","key":"zoi220863r6","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1212\/01.wnl.0000312276.23177.fa","article-title":"Cognitive and psychosocial features of childhood and juvenile MS.","volume":"70","author":"Amato","year":"2008","journal-title":"Neurology"},{"issue":"16","key":"zoi220863r7","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1212\/01.wnl.0000259407.40023.ab","article-title":"Treatment of pediatric multiple sclerosis and variants.","volume":"68","author":"Pohl","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"zoi220863r8","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view.","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult Scler"},{"issue":"3","key":"zoi220863r9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1352458520930620","article-title":"The introduction of new medications in pediatric multiple sclerosis: open issues and challenges.","volume":"27","author":"Ghezzi","year":"2021","journal-title":"Mult Scler"},{"key":"zoi220863r10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/PHMT","article-title":"Review of the safety, efficacy and tolerability of fingolimod in the treatment of pediatric patients with relapsing-remitting forms of multiple sclerosis (RRMS).","volume":"10","author":"Feng","year":"2019","journal-title":"Pediatric Health Med Ther"},{"issue":"6","key":"zoi220863r11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40272-021-00471-1","article-title":"Teriflunomide: pediatric first approval.","volume":"23","author":"Paik","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"12","key":"zoi220863r12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi220863r13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"zoi220863r14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","article-title":"Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY).","volume":"22","author":"Cohan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"zoi220863r15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results.","volume":"28","author":"Gold","year":"2022","journal-title":"Mult Scler"},{"key":"zoi220863r16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS).","volume":"83","author":"Alroughani","year":"2018","journal-title":"Pediatr Neurol"},{"key":"zoi220863r17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2016.01.010","article-title":"Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study.","volume":"57","author":"Makhani","year":"2016","journal-title":"Pediatr Neurol"},{"key":"zoi220863r18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.606418","article-title":"Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis.","volume":"11","author":"Alroughani","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"zoi220863r19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.v88.1","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis.","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann Neurol"},{"issue":"4","key":"zoi220863r20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom.","volume":"8","author":"Abdel-Mannan","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"zoi220863r21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1586\/14737175.5.3.403","article-title":"Childhood-juvenile multiple sclerosis: clinical characteristics and treatment.","volume":"5","author":"Ghezzi","year":"2005","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"zoi220863r22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0887-8994(99)00007-7","article-title":"Interferon beta-1b and childhood multiple sclerosis.","volume":"21","author":"Adams","year":"1999","journal-title":"Pediatr Neurol"},{"issue":"3","key":"zoi220863r23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1067\/mpd.2001.117004","article-title":"Interferon-beta treatment in patients with childhood-onset multiple sclerosis.","volume":"139","author":"Mikaeloff","year":"2001","journal-title":"J Pediatr"},{"issue":"5","key":"zoi220863r24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1212\/01.WNL.0000153570.33845.6A","article-title":"Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.","volume":"64","author":"Pohl","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"zoi220863r25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11940-009-0024-6","article-title":"Pediatric multiple sclerosis.","volume":"11","author":"Waubant","year":"2009","journal-title":"Curr Treat Options Neurol"},{"issue":"16","key":"zoi220863r26","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1212\/01.wnl.0000259422.44235.a8","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders.","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"zoi220863r27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"issue":"1","key":"zoi220863r29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/135245859700300105","article-title":"Multiple sclerosis in childhood: clinical features of 149 cases.","volume":"3","author":"Ghezzi","year":"1997","journal-title":"Mult Scler"},{"issue":"1","key":"zoi220863r30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis.","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler"},{"issue":"8","key":"zoi220863r31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch Neurol"},{"issue":"6","key":"zoi220863r32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ejpn.2019.08.007","article-title":"Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis.","volume":"23","author":"Johnen","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"zoi220863r33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/jnnp-2019-321124","article-title":"Consistent control of disease activity with fingolimod versus IFN \u00df-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS.","volume":"91","author":"Deiva","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"zoi220863r28","author":"Soman","year":"2015"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796813\/vermersch_2022_oi_220863_1663774098.18005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:34:28Z","timestamp":1664379268000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796813"}},"subtitle":["The CONNECT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.30439","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}